Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 2191-2206

  Murugan, Karmani ^a   Choonara, Yahya E ^a   Kumar, Pradeep ^a   Bijukumar, Divya ^a   du Toit, Lisa C ^a   Pillay, Viness ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cellular uptake; Charge; Nanoparticles; Shape; Size; Transport mechanisms

Indexed keywords

CAVEOLIN; CELL ADHESION MOLECULE; CELL PENETRATING PEPTIDE; MACROGOL; NANOMATERIAL; POLYGLACTIN; LIGAND; NANOPARTICLE; PROTEIN;

ARTICLE; CAVEOLA; COMPLEX FORMATION; DRUG RELEASE; ENCAPSULATION; ENDOCYTOSIS; HUMAN; HYDROPHOBICITY; INTERNALIZATION; LIPID BILAYER; NANOMEDICINE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OPSONIZATION; PARTICLE SIZE; PERMEABILITY BARRIER; PHAGOCYTOSIS; PINOCYTOSIS; SURFACE CHARGE; SURFACE PROPERTY; TRANSCYTOSIS; TRANSPORT KINETICS; CHEMICAL PHENOMENA; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; NANOMEDICINE; NANOPARTICLES; NANOSTRUCTURES; PARTICLE SIZE; PROTEINS; SURFACE PROPERTIES;

EID: 84928128382     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S75615     Document Type: Article

References (145)

1. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother. 2004;58(3):168-172.
2. Gratton SE, Napier ME, Ropp PA, Tian S, DeSimone JM. Microfabricated particles for engineered drug therapies: elucidation into the mechanisms of cellular internalization of PRINT particles. Pharm Res. 2008;25(12):2845-2852.
3. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2):147-166.
4. Brzoska M, Langer K, Coester C, Loitsch S, Wagner TO, Mallinckrodt C. Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem Biophys Res Commun. 2004;318(2):562-570.
5. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18.
6. Xiang S, Tong H, Shi Q, et al. Uptake mechanisms of non-viral gene delivery. J Control Release. 2012;158(3):371-378.
7. Mousavi S, Malerd L, Berg T, Kjeken R. Clathrin-dependent endocytosis. Biochem J. 2004;377:1-16.
8. Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev. 2012;65(1):121-138.
9. Kumari S, Mg S, Mayor S. Endocytosis unplugged: multiple ways to enter the cell. Cell Res. 2010;20(3):256-275.
10. Pelkmans L, Püntener D, Helenius A. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science. 2002;296(5567):535-539.
11. Wang Z, Tiruppathi C, Minshall RD, Malik AB. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano. 2009;3(12):4110-4116.
12. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145(3):182-195.
13. Kerr MC, Teasdale RD. Defining macropinocytosis. Traffic. 2009;10(4):364-371.
14. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009;66(17):2873-2896.
15. Groves E, Dart A, Covarelli V, Caron E. Molecular mechanisms of phagocytic uptake in mammalian cells. Cell Mol Life Sci. 2008;65(13):1957-1976.
16. Park H, Cox D. Cdc42 regulates Fcγ receptor-mediated phagocytosis through the activation and phosphorylation of Wiskott-Aldrich syndrome protein (WASP) and neural-WASP. Mol Biol Cell. 2009; 20(21):4500-4508.
17. Bomsel M, Prydz K, Parton RG, Gruenberg J, Simons K. Endocytosis in filter-grown Madin-Darby canine kidney cells. J Cell Biol. 1989;109(6):3243-3258.
18. Gonzalez-Mariscal L, Hernández S, Vega J. Inventions designed to enhance drug delivery across epithelial and endothelial cells through the paracellular pathway. Recent Pat Drug Deliv Formul. 2008;2(2):145-176.
19. Mostov KE. Transepithelial transport of immunoglobulins. Annu Rev Immunol. 1994;12(1):63-84.
20. Lu W, Xiong C, Zhang R, et al. Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors. J Control Release. 2012;161(3):959-966.
21. Ferrati S, McConnell KI, Mack AC, et al. Cellular communication via nanoparticle-transporting biovesicles. Nanomedicine (Lond). 2014;9(5):581-592.
22. Hayashi M, Tomita M, Awazu S. Transcellular and paracellular contribution to transport processes in the colorectal route. Adv Drug Deliv Rev. 1997;28(2):191-204.
23. Salamat-Miller N, Johnston TP. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm. 2005;294(1):201-216.
24. Mohanraj V, Chen Y. Nanoparticles - a review. Trop J Pharm Res. 2007;5(1):561-573.
25. Reddy ST, Berk DA, Jain RK, Swartz MA. A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J Appl Physiol (1985). 2006;101(4):1162-1169.
26. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol. 2012;52:481-503.
27. Barua S, Rege, K. Cancer-cell-phenotype-dependent differential intracellular trafficking of unconjugated quantum dots. Small. 2009;5(3):370-376.
28. Snijder B, Sacher R, Rämö P, Damm EM, Liberali P, Pelkmans L. Population context determines cell-to-cell variability in endocytosis and virus infection. Nature. 2009;461(7263):520-523.
29. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009;61(6):428-437.
30. Gunaseelan S, Gunaseelan K, Deshmukh M, Zhang X, Sinko PJ. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv Drug Deliv Rev. 2010;62(4):518-531.
31. Torrano AA, Blechinger J, Osseforth C, et al. A fast analysis method to quantify nanoparticle uptake on a single cell level. Nanomedicine (Lond). 2013;8(11):1815-1828.
32. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release. 2006;114(1):53-59.
33. des Rieux A, Fievez V, Garinot M, Schneider Y, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116(1):1-27.
34. Acosta E. Bioavailability of nanoparticles in nutrient and nutraceutical delivery. Curr Opin Colloid Interface Sci. 2009;14(1):3-15.
35. Patel NR, Damann K, Leonardi C, Sabliov CM. Size dependency of PLGA-nanoparticle uptake and antifungal activity against Aspergillus flavus. Nanomedicine (Lond). 2011;6(8):1381-1395.
36. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006;6(4):662-668.
37. Jin H, Heller DA, Sharma R, Strano MS. Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. ACS Nano. 2009;3(1):149-158.
38. Awaad A, Nakamura M, Ishimura K. Imaging of size-dependent uptake and identification of novel pathways in mouse Peyer's patches using fluorescent organosilica particles. Nanomedicine. 2012;8(5):627-636.
39. Roger E, Lagarce F, Garcion E, Benoit J. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009;140(2):174-181.
40. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng. 2006;8:343-375.
41. Nicolete R, Dos Santos DF, Faccioli LH. The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response. Int Immunopharmacol. 2011;11(10):1557-1563.
42. Loh JW, Saunders M, Lim LY. Cytotoxicity of monodispersed chitosan nanoparticles against the Caco-2 cells. Toxicol Appl Pharmacol. 2012;262(3):273-282.
43. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules. 2008;9(2):435-443.
44. Nan A, Bai X, Son SJ, Lee SB, Ghandehari H. Cellular uptake and cytotoxicity of silica nanotubes. Nano Lett. 2008;8(8):2150-2154.
45. Ilina P, Hyvonen Z, Saura M, Sandvig K, Yliperttula M, Ruponen M. Genetic block of endocytic pathways reveals differences in the intracellular processing of non-viral gene delivery systems. J Control Release. 2012;163(3):385-395.
46. Rand RP. Interacting phospholipid bilayers: measured forces and induced structural changes. Annu Rev Biophys Bioeng. 1981;10:277-314.
47. Jallouli Y, Paillard A, Chang J, Sevin E, Betbeder D. Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int J Pharm. 2007;344(1-2):103-109.
48. Karlsson J, Ungell A, Gråsjö J, Artursson P. Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux. Eur J Pharm Sci. 1999;9(1):47-56.
49. Lin IC, Liang M, Liu TY, Monteiro MJ, Toth I. Cellular transport pathways of polymer coated gold nanoparticles. Nanomedicine. 2012;8(1):8-11.
50. Zhang LW, Monteiro-Riviere NA. Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol Sci. 2009;110(1):138-155.
51. Muthu MS, Singh S. Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation. Nanomedicine (Lond). 2008;3(3):305-319.
52. Champion JA, Katare YK, Mitragotri S. Making polymeric micro-and nanoparticles of complex shapes. Proc Natl Acad Sci U S A. 2007;104(29):11901-11904.
53. Hao N, Li L, Zhang Q, et al. The shape effect of PEGylated mesoporous silica nanoparticles on cellular uptake pathway in Hela cells. Microporous Mesoporous Mater. 2012;162:14-23.
54. Han Y, Alsayed A, Nobili M, Zhang J, Lubensky TC, Yodh AG. Brownian motion of an ellipsoid. Science. 2006;314(5799):626-630.
55. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A. 2006;103(13):4930-4934.
56. Yang K, Ma YQ. Computer simulation of the translocation of nanoparticles with different shapes across a lipid bilayer. Nat Nanotechnol. 2010;5(8):579-583.
57. Gratton SE, Ropp PA, Pohlhaus PD. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105(33):11613-11618.
58. Sadeghi B, Garmaroudi FS, Hashemi M, et al. Comparison of the anti-bacterial activity on the nanosilver shapes: nanoparticles, nanorods and nanoplates. Adv Powder Technol. 2012;23(1):22-26.
59. Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2010;141(3):320-327.
60. Park JH, von Maltzahn G, Zhang L, et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small. 2009;5(6):694-700.
61. Devarajan PV, Jindal AB, Patil RR, Mulla F, Gaikwad RV, Samad A. Particle shape: a new design parameter for passive targeting in splenotropic drug delivery. J Pharm Sci. 2010;99(6):2576-2581.
62. Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release. 2012;166(2):182-194.
63. Howard KA, Peer D. Providing the full picture: a mandate for standardizing nanoparticle-based drug delivery. Nanomedicine (Lond). 2013;8(7):1031-1033.
64. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2077;2(8):469-478.
65. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102.
66. Chiu YL, Ho YC, Chen YM, et al. The characteristics, cellular uptake and intracellular trafficking of nanoparticles made of hydrophobically-modified chitosan. J Control Release. 2010;146(1):152-159.
67. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631-651.
68. Gomes-da-Silva LC, Fernández Y, Abasolo I, et al. Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform. Nanomedicine (Lond). 2013;8(9):1397-1413.
69. Sonaje K, Lin KJ, Tseng MT, et al. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials. 2011;32(33):8712-8721.
70. Sambruy Y, Ferruzza S, Ranaldi G, De Angelis I. Intestinal cell culture models: applications in toxicology and pharmacology. Cell Biol Toxicol. 2001;17(4-5):301-317.
71. Luk BT, Hu CM, Fang RH, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale. 2014;6(5):2730-2737.
72. Lin TY, Li YP, Zhang H, et al. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (Lond). 2013;8(8):1239-1251.
73. Loureiro JA, Gomes B, Coelho MA, Carmo Pereira MD, Rocha S. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies. Nanomedicine (Lond). 2014;9(5):709-722.
74. Patel LN, Zaro JL, Shen W. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res. 2077;24(11):1977-1992.
75. Jones AT. Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides. Int J Pharm. 2008;354(1-2):34-38.
76. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59(8):748-758.
77. Pujals S, Giralt E. Proline-rich, amphipathic cell-penetrating peptides. Adv Drug Deliv Rev. 2008;60(4-5):473-484.
78. Oh P, Borgström P, Witkiewicz H, et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol. 2007;25(3):327-337.
79. Oba M, Aoyagi K, Miyata K, et al. Polyplex micelles with cyclic RGD peptide ligands and disulfide cross-links directing to the enhanced transfection via controlled intracellular trafficking. Mol Pharm. 2008;5(6):1080-1092.
80. Liu J, KopeckováP, Bühler P, et al. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm. 2009;6(3):959-970.
81. Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer. 2004;112(2):335-340.
82. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release. 2007;120(1):18-26.
83. Huang X, Peng X, Wang Y. A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano. 2010;4(10):5887-5896.
84. Temsamani J, Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov Today. 2004;9(23):1012-1019.
85. Patel PC, Giljohann DA, Daniel WL, Zheng D, Prigodich AE, Mirkin CA. Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. Bioconjug Chem. 2010;21(12):2250-2256.
86. Liu Y, Shipton MK, Ryan J, et al. Synthesis, stability, and cellular internalization of gold nanoparticles containing mixed peptide-poly(ethylene glycol) monolayers. Anal Chem. 2007;79(6):2221-2229.
87. Fortier C, Durocher Y, De Crescenzo G. Surface modification of non-viral nanocarriers for enhanced gene delivery. Nanomedicine (Lond). 2014;9(1):135-151.
88. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649-1659.
89. Vllasaliu D, Fowler R, Garnett M, Eaton M, Stolnik S. Barrier characteristics of epithelial cultures modelling the airway and intestinal mucosa: a comparison. Biochem Biophys Res Commun. 2011;415(4):579-585.
90. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol. 2010;28(4):181-188.
91. Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, Yamashita S. Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci. 2006;29(3-4):240-250.
92. Kuo TR, Wu CL, Hsu CT, et al. Chemical enhancer induced changes in the mechanisms of transdermal delivery of zinc oxide nanoparticles. Biomaterials. 2009;30(16):3002-3008.
93. Chen-yu G, Chun-fen Y, Qi-lu L, et al. Development of a quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm. 2012;430(1-2):292-298.
94. Baroli B, Ennas MG, Loffredo F, Isola M, Pinna R, López-Quintela MA. Penetration of metallic nanoparticles in human full-thickness skin. J Invest Dermatol. 2007;127(7):1701-1712.
95. Shim J, Seok Kang H, Park WS, Han SH, Kim J, Chang IS. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Release. 2004;97(3):477-484.
96. Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicol Sci. 2006;91(1):159-165.
97. Wang J, Chen J, Ye N, et al. Absorption, pharmacokinetics and disposition properties of solid lipid nanoparticles (SLNs). Curr Drug Metab. 2012;13(4):447-456.
98. Ting SR, Whitelock JM, Tomic R, et al. Cellular uptake and activity of heparin functionalised cerium oxide nanoparticles in monocytes. Biomaterials. 2013;34(17):4377-4386.
99. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine. 2010;6(2):324-333.
100. Freddo TF. A contemporary concept of the blood-aqueous barrier. Prog Retin Eye Res. 2012;32:181-195.
101. Guinedi AS, Mortada ND, Mansour S, Hathout RM. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm. 2005;306(1-2):71-82.
102. de la Fuente M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev. 2010;62(1):100-117.
103. Mautes AE, Weinzierl MR, Donovan F, Noble LJ. Vascular events after spinal cord injury: contribution to secondary pathogenesis. Phys Ther. 2000;80(7):673-687.
104. Das M, Patil S, Bhargava N. Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons. Biomaterials. 2007;28(10):1918-1925.
105. Garcia-Garcia E, Andrieux K, Gil S, et al. A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int J Pharm. 2005;298(2):310-314.
106. Costantino L, Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today. 2012;17(7):367-378.
107. Hynynen K. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev. 2008;60(10):1209-1217.
108. Stam R. Electromagnetic fields and the blood-brain barrier. Brain Res Rev. 2010;65(1):80-97.
109. Reid DM, Perry VH, Andersson PB, Gordon S. Mitosis and apoptosis of microglia in vivo induced by an anti-CR3 antibody which crosses the blood-brain barrier. Neuroscience. 1993;56(3):529-533.
110. Kuo YC, Lee CL. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. Colloids Surf B Biointerfaces. 2012;90:75-82.
111. Dhanikula RS, Argaw A, Bouchard J, Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm. 2008;5(1):105-116.
112. Pang Z, Gao H, Yu Y, et al. Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes. Int J Pharm. 2011;415(1):284-292.
113. Martins S, Tho I, Reimold I, et al. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies. Int J Pharm. 2012;439(1-2):49-62.
114. Wen CJ, Yen TC, Al-Suwayeh SA, Chang HW, Fang JY. In vivo real-time fluorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester: oil ratios. Nanomedicine (Lond). 2011;6(9):1545-1559.
115. Thorne RG, Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci U S A. 2006;103(14):5567-5572.
116. Zhang X, Chen G, Wen L, et al. Novel multiple agents loaded PLGA nanoparticles for brain delivery via inner ear administration: in vitro and in vivo evaluation. Eur J Pharm Sci. 2013;48(4-5):595-603.
117. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379(1):146-157.
118. Geng Y, Dalhaimer P, Cai S, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol. 2007;2(4):249-255.
119. Jacobs F, Wisse E, De Geest B. The role of liver sinusoidal cells in hepatocyte-directed gene transfer. Am J Pathol. 2010;176(1):14-21.
120. Johnston HJ, Semmler-Behnke M, Brown DM, Kreyling W, Tran L, Stone V. Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicol Appl Pharmacol. 2010;242(1):66-78.
121. Lin A, Liu Y, Huang Y, et al. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery. Int J Pharm. 2008;359(1):247-253.
122. Kim TH, Park IK, Nah JW, Choi YJ, Cho CS. Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials. 2004;25(17):3783-3792.
123. Doshi N, Mitragotri S. Macrophages recognize size and shape of their targets. PLoS One. 2010;5(4):e10051.
124. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158-171.
125. Madhav NV, Shakya AK, Shakya P, Singh K. Orotransmucosal drug delivery systems: a review. J Control Release. 2009;140(1-2):2-11.
126. Teubl BJ, Absenger M, Fröhlich E, Leitinger G, Zimmer A, Roblegg E. The oral cavity as a biological barrier system: design of an advanced buccal in vitro permeability model. Eur J Pharm Biopharm. 2013;84(2):386-393.
127. Kochut A, Dersch P. Bacterial invasion factors: tools for crossing biological barriers and drug delivery? Eur J Pharm Biopharm. 2013;84(2):242-250.
128. Coco R, Plapied L, Pourcelle V, et al. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm. 2012;440(1):3-12.
129. Yang M, Lai SK, Wang YY, et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew Chem Int Ed Engl. 2011;50(11):2597-2600.
130. O'Neill MJ, Guo J, Byrne C, Darcy R, O'Driscoll CM. Mechanistic studies on the uptake and intracellular trafficking of novel cyclodextrin transfection complexes by intestinal epithelial cells. Int J Pharm. 2011;413(1-2):174-183.
131. des Rieux A, Ragnarsson EG, Gullberg E, Préat V, Schneider YJ, Artursson P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur J Pharm Sci. 2055;25(4):455-465.
132. Brandenberger C, Rothen-Rutishauser B, Mühlfeld C, et al. Effects and uptake of gold nanoparticles deposited at the air-liquid interface of a human epithelial airway model. Toxicol Appl Pharmacol. 2010;242(1):56-65.
133. Rotoli BM, Bussolati O, Bianchi MG, et al. Non-functionalized multi-walled carbon nanotubes alter the paracellular permeability of human airway epithelial cells. Toxicol Lett. 2008;178(2):95-102.
134. Wanakule P, Liu GW, Fleury AT, Roy K. Nano-inside-micro: disease-responsive microgels with encapsulated nanoparticles for intracellular drug delivery to the deep lung. J Control Release. 2012;162(2):429-437.
135. Vllasaliu D, Alexander C, Garnett M, Eaton M, Stolnik S. Fc-mediated transport of nanoparticles across airway epithelial cell layers. J Control Release. 2012;158(3):479-486.
136. Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451-487.
137. He B, Jia Z, Du W. The transport pathways of polymer nanoparticles in MDCK epithelial cells. Biomaterials. 2013;34(17):4309-4326.
138. Christensen EI, Verroust PJ, Nielsen R. Receptor-mediated endocytosis in renal proximal tubule. Pflugers Arch. 2009;458(6):1039-1048.
139. Bertrand N, Leroux JC. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release. 2012;161(2):152-163.
140. Kodaira H, Tsutsumi Y, Yoshioka Y, et al. The targeting of anionized polyvinylpyrrolidone to the renal system. Biomaterials. 2004;25(18):4309-4315.
141. Yamamoto Y, Tsutsumi Y, Yoshioka Y, et al. Poly(vinylpyrrolidone-co-dimethyl maleic acid) as a novel renal targeting carrier. J Control Release. 2004;95(2):229-237.
142. Yuan ZX, Zhang ZR, Zhu D, et al. Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan. Mol Pharm. 2008;6(1):305-314.
143. Narayanan K, Yen SK, Dou Q, et al. Mimicking cellular transport mechanism in stem cells through endosomal escape of new peptide-coated quantum dots. Sci Rep. 2013;3:2184.
144. Tkachenko AG, Xie H, Coleman D, et al. Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. J Am Chem Soc. 2003;125(16):4700-4701.
145. Chen J, Wu C, Oupický D. Bioreducible hyperbranched poly(amido amine)s for gene delivery. Biomacromolecules. 2009;10(10):2921-2927.